| Bioactivity | Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1). | |||||||||
| Name | Bafrekalant | |||||||||
| CAS | 2256770-44-0 | |||||||||
| Formula | C29H31ClN6O2 | |||||||||
| Molar Mass | 531.05 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Martina Delbeck, et al. Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders. Patent WO2018228907A1. |
Bafrekalant
CAS: 2256770-44-0 F: C29H31ClN6O2 W: 531.05
Bafrekalant is a diazabicyclic substituted imidazopyrimidine-derivative. Bafrekalant has the potential for the research
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.